New cocktail aims to shrink stomach tumors

NCT ID NCT07356466

ENROLLING_BY_INVITATION Disease control Sponsor: Fujian Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether adding two drugs—pucotenlimab (an immunotherapy) and lenvatinib (a targeted therapy)—to standard chemotherapy (SOX) can shrink tumors better than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction cancer. About 100 participants will be randomly assigned to one of the two treatment groups. The main goal is to see how many patients have their tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pucotenlimab (an immunotherapy drug) combined with lenvatinib (a targeted therapy) and SOX chemotherapy (oxaliplatin plus S-1)
What this could lead to: If successful, this combination could offer a new, more effective treatment option for people with advanced stomach cancer that is not curable with current therapies.
What could go wrong: This is a very early (Phase 1) and small trial, so results may not be conclusive. The added drugs may cause more side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC (STOMACH) CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC (STOMACH) CANCER

Contacts and locations

Locations

Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.